Thus, we intended to further evaluate the safety, tolerability, efficacy and PK profile of different doses of BPI-9016M in patients with locally advanced or metastatic NSCLC harboring c-MET overexpression or MET exon 14 skipping mutation. This evidence concerns the gene MET and non-small cell lung carcinoma.